Kurtis D. Davies is an Assistant Professor in the Department of Pathology at the University of Colorado – Anschutz Medical Campus, and he serves as the Lead Assay Development Scientist in the Colorado Molecular Correlates Laboratory. He received his Ph.D. from the Department of Pharmacology at the University of Colorado while investigating molecular mechanisms that underlie synaptic plasticity in hippocampal neurons. He then completed a post-doctoral fellowship at Array BioPharma, with a primary focus on determining the antiproliferative mechanism of action of single-agent CHK1 inhibition in cancer cells. A second post-doctoral fellowship at CU entailed establishing ROS1 gene fusions as therapeutic targets in non-small cell lung cancer.
Dr. Davies’ current research interests are largely focused on clinically actionable gene fusions in cancer. He has published several high impact manuscripts describing the identification of novel drug target gene fusions and outlining the complexities of gene fusion detection in clinical tumor samples.
